Abstract 523P
Background
The aim of this study was to investigate the impact of main co-morbidities in China: hypertension, type 2 diabetes and chronic hepatitis B viral (HBV) infection on overall survival of patients with extensive-stage small-cell lung cancer (SCLC).
Methods
Between 2009 and 2018, patients with pathologically diagnosis of SCLC in our hospital were reviewed, and the extensive stage cases were recruited in present study. Patients were divided into hypertension and non-hypertension, diabetes and non-diabetes, HBV-positive and HBV-negative group. The overall survival (OS) was evaluated using the Kaplan-Meier method and Cox proportional hazard models in each group respectively. This work was approved by the West China Hospital Research Ethics Board.
Results
Totally, 1345 SCLC patients were reviewed. 632 patients (46.9%) were confirmed with extensive-stage SCLC and analyzed. The median OS in present study was 14.6 months (95% confidence interval (CI) 13.8-15.4 months). The OS of patients with type 2 diabetes (median 17.3 months, 95% CI 14.9-19.8 months) and HBV infection (median 19.9 months, 95% CI 16.1-23.7 months) were significantly improved, comparing to the patients without diabetes (median 14.2 months, 95% CI 13.4-15.1 months) and HBV infection (median 14.2 months, 95% CI 13.4-15.0 months), respectively (p < 0.05). No significant difference in OS was observed in hypertension and non-hypertension group (median 15.7 vs. 14.4 months, p > 0.05). The prognosis significantly decreased if the patients with type 2 diabetes (HR = 0.78, 95% CI: 0.62-0.99, p = 0.046) and HBV infection (HR = 0.61, 95% CI: 0.45-0.83, p = 0.001), comparing to those patients without diabetes or HBV infection.
Conclusions
Present data indicated that the co-morbidities (type 2 diabetes and HBV infection) might be associated with the favorable prognosis in extensive-stage SCLC patients. Prospective studies are warranted to verify our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract